Objective    To investigate the antitumor effect of special promoter-controlled Gibbon ape leukemia virus membrane fusion glycoprotein (GALV.fus) mediated by type Ⅰ herpes simplex virus (HSV-Ⅰ) on lung adenocarcinoma.     Methods    Recombinant HSV-Ⅰ plasmids encoding GALV.fus was introduced into green monkey kidney cells（Vero）by liposome to amplify the virus

and then the virus was transfected into lung adenocarcinoma (A549)

human fetal fibroblasts (HFL-Ⅰ GNHu 5) and human lung adenocarcinoma xenografts which were established in nude mice subcutaneously to observe antitumor and cytotoxic effect in vitro and in vivo; Recombined cytomegalovirus (CMV) containing GALV.fus or enhanced green fluorescence protein were served as control.     Results    Recombinant HSV-Ⅰ virus were packed successfully. Heterotransplantative tumourigenicity of the tumour was 100% in nude mice after A549 cells were inoculated. Recombinant HSV-Ⅰvirus exerted obvious antitumor effects in vitro

with relative survival rate of 23%

while for CMV virus containing GALV. fus

the rate was 20%

and for CMV virus encoding EGFP

the rate was 68%. Recombinant HSV-Ⅰvirus also showed striking antitumor effect on the implanted tumor.     Conclusion    GALV.fus has powerful effect against lung cancer in vitro and in vivo and maybe a promising candidate for gene therapy.